Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in moderate-to-severe atopic dermatitis
NCT03563066Phase 2Completed
- Sponsor
- McMaster University
- Start
- Sep 2018
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benralizumab in atopic dermatitis (AD), sponsored by McMaster University. Started Sep 2018; status: completed.
02
Drugs
benralizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03563066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03563066.